ResMed makes remote monitoring devices and software for sleep apnea patients. Combined with Verily's data analytics technologies, the companies will try to drill down on the health and financial impacts of undiagnosed and untreated sleep apnea.
The goal is to develop software that can be used by healthcare professionals to identify, diagnose, treat and manage sleep apnea in patients.
Interestingly, the companies are formalizing their partnership as a full scale joint venture, complete with customary closing conditions and regulatory approvals. The joint venture will be based in the US and operate as a separate venture from ResMed and Verily, the companies said.
"Approaching a widespread health problem like sleep apnea through collecting, organizing and activating health data is central to Verily's mission," said Jessica Mega, chief medical and scientific officer at Verily.
"By better identifying at-risk individuals as well as generating real-world evidence regarding the value and effectiveness of treatment, this collaboration has the potential to improve outcomes for millions of people living with sleep apnea, and potentially other related conditions."